RemeGen announced the latest clinical research results on disitamab vedotin (RC48) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Researchers tested disitamab vedotin and toripalimab in combination on patients diagnosed with locally advanced or metastatic urothelial carcinoma (la/mUC). The objective of the study was to determine the safety and efficacy of this […]
